Product image of Imipenem + Cilastatina Venus Pharma (Cilastatin, Imipenem) supplied by GNH India

Imipenem + Cilastatina Venus Pharma

Active Ingredient:
Cilastatin, Imipenem
Origin:
EU

Imipenem + Cilastatina Venus Pharma (Cilastatin, Imipenem)

Imipenem/cilastatin, the active ingredient in Imipenem + Cilastatina Venus Pharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, febrile neutropenia, and nosocomial pneumonia in hospitalized patients.

GNH India supplies Imipenem + Cilastatina Venus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Venus Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/cilastatin is used for a range of serious bacterial infections that require intravenous therapy.

  • Complicated intra‑abdominal infections: provides broad‑spectrum bacterial coverage to resolve infection.
  • Complicated urinary tract infections: eliminates resistant uropathogens and restores urinary sterility.
  • Complicated skin and soft tissue infections: eradicates mixed Gram‑positive and Gram‑negative organisms.
  • Febrile neutropenia: offers rapid bactericidal activity in immunocompromised patients.
  • Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant bacteria.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting bacterial cell‑wall peptidoglycan synthesis and causing cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and extending its antibacterial activity in the body.

Side Effects

Adverse reactions may occur with imipenem/cilastatin therapy and are categorized by frequency.

Common Side Effects

  • Nausea
  • Diarrhea
  • Headache
  • Rash
  • Elevated liver enzymes
  • Injection‑site phlebitis

Serious or Rare Side Effects

  • Seizures
  • Severe allergic reactions (anaphylaxis)
  • Clostridioides difficile‑associated colitis
  • Renal impairment
  • Thrombocytopenia
  • Neutropenia

Precautions & Warnings

When prescribing imipenem/cilastatin, clinicians should consider several safety aspects.

  • Renal function: adjust dose in patients with impaired renal clearance.
  • Seizure risk: monitor patients with a history of CNS disorders or receiving concomitant neurotoxic drugs.
  • Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactam antibiotics.
  • Drug interactions: review concomitant medications that may lower seizure threshold or affect renal excretion.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Imipenem/cilastatin may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid)

  • Valproic acid: co‑administration reduces valproate levels, risking loss of seizure control.
  • Other carbapenems: concurrent use may increase neurotoxicity and renal burden.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance nephrotoxic potential.
  • Aminoglycosides: combined use can increase risk of renal impairment.
  • NSAIDs: may further compromise renal function.
  • Warfarin: imipenem can alter INR, requiring closer monitoring.
  • Oral contraceptives: efficacy may be reduced, advise additional contraceptive measures.

Frequently Asked Questions

Imipenem + Cilastatina is indicated for serious bacterial infections that require intravenous therapy, including complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, febrile neutropenia, and nosocomial pneumonia.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin prevents renal dehydropeptidase I from degrading imipenem, thereby maintaining effective drug concentrations in the body.

The dosage and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against many Gram‑positive, Gram‑negative and anaerobic bacteria, similar to other carbapenems like meropenem. Its co‑formulation with cilastatin protects the drug from renal degradation, allowing higher and more sustained plasma concentrations.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, it should be used within the time frame specified in the product labeling.

It is given as an intravenous infusion. The exact infusion rate and duration are set by the prescriber, who will consider the infection severity, patient condition, and compatibility with other IV solutions.

Serious adverse events include seizures, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, renal impairment, and hematologic abnormalities like thrombocytopenia or neutropenia. Prompt medical attention is required if these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, other carbapenems, or any β‑lactam antibiotics should not receive this medication. Caution is also advised for individuals with a history of seizures or severe renal dysfunction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT